Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.
The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.
Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.
The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.